The American Journal of Medicine
Volume 121, Issue 2 , Pages 91-97 , February 2008

Advising Patients Who Use Dietary Supplements

References 

  1. Dietary Supplement Health and Education Act of 1994 (Public Law 103-417). http://www.fda.gov/opacom/laws/dshea.htmlAccessed September 27, 2006
  2. NIH State-of-the-Science Conference Statement on Multivitamin/Mineral Supplements and Chronic Disease Prevention. NIH Consens State Sci Statements. 2006;23:1–30
  3. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data. 2004;(343):1–19Available at: http://www.cdc.gov/nchs/data/ad/ad343.pdf. Accessed October 8, 2006
  4. Palmer ME, Haller C, McKinney PE, et al. Adverse events associated with dietary supplements: an observational study. Lancet. 2003;361:101–106
  5. Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs. 2005;65:1239–1282
  6. Fugh-Berman A. Herb-drug interactions. Lancet. 2000;355:134–138
  7. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287:337–344
  8. Robinson A, McGrail MR. Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies. Complement Ther Med. 2004;12:90–98
  9. Armstrong K, Rose A, Peters N, et al. Distrust of the health care system and self-reported health in the United States. J Gen Intern Med. 2006;21:292–297
  10. Ashar BH, Miller RG, Getz KJ, Pichard CP. A critical evaluation of Internet marketing of products that contain ephedra. Mayo Clin Proc. 2003;78:944–946
  11. Morris CA, Avorn J. Internet marketing of herbal products. JAMA. 2003;290:1505–1509
  12. The Federal Trade Commission. Dietary supplements: an advertising guide for industry. http://www.ftc.gov/bcp/conline/pubs/buspubs/dietsupp.htmAccessed October 8, 2006
  13. The Federal Trade Commission. FTC testifies on the marketing of dietary supplements. http://www.ftc.gov/opa/2003/10/dietarysupptest.htmAccessed October 8, 2006
  14. The Regulation of Dietary Supplements (Prepared statement of the Federal Trade Commission). http://www.ftc.gov/os/2006/03/P064502CommissionTestimonyConcerningtheRegulationofDietarySupplements.pdfAccessed January 2, 2007
  15. Mandelblatt J, Kreling B, Figeuriedo M, Feng S. What is the impact of shared decision making on treatment and outcomes for older women with breast cancer?. J Clin Oncol. 2006;24(30):4908–4913
  16. Adler SR, Fosket JR. Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer. J Fam Pract. 1999;48:453–458
  17. Crock RD, Jarjoura D, Polen A, Rutecki GW. Confronting the communication gap between conventional and alternative medicine: A survey of physicians’ attitudes. Altern Ther Health Med. 1999;5:61–66
  18. Astin JA, Marie A, Pelletier KR, et al. A review of the incorporation of complementary and alternative medicine by mainstream physicians. Arch Intern Med. 1998;158:2303–2310
  19. Corbin Winslow L, Shapiro H. Physicians want education about complementary and alternative medicine to enhance communication with their patients. Arch Intern Med. 2002;162(10):1176–1181
  20. Wynia MK, Eisenberg DM, Wilson IB. Physician-patient communication about complementary and alternative medical therapies: a survey of physicians caring for patients with human immunodeficiency virus infection. J Altern Complement Med. 1999;5:447–456
  21. Roberts CS, Baker F, Hann D, et al. Patient-physician communication regarding use of complementary therapies during cancer treatment. J Psychosoc Oncol. 2005;23:35–60
  22. Alvins AL, Bent S. Saw palmetto and lower urinary tract symptoms: what is the latest evidence?. Curr Urol Rep. 2006;7:260–265
  23. Bonnar-Pizzorno RM, Littman AJ, Kestin M, White E. Saw palmetto supplement use and prostate cancer risk. Nutr Cancer. 2006;55:21–27
  24. Silverstein DD, Spiegel AD. Are physicians aware of the risks of alternative medicine?. J Community Health. 2001;26:159–174
  25. U.S. Food and Drug Administration. Overview of dietary supplements. http://www.cfsan.fda.gov/∼dms/supplmnt.htmlAccessed September 27, 2006
  26. Gilroy CM, Steiner JF, Byers T, et al. Echinacea and truth in labeling. Arch Intern Med. 2003;163:699–704
  27. Cole MR, Fetrow CW. Adulteration of dietary supplements. Am J Health Syst Pharm. 2003;60:1576–1580
  28. US National Institutes of HealthNational Cancer Institute. Questions and answers about PC-SPES. 2007;Available at: http://www.cancer.gov/cancertopics/pdq/cam/pc-spes/Patient/Page2#Section_5. Accessed December 27
  29. Blendon RJ, DesRoches CM, Benson JM, et al. Americans views on the use and regulation of dietary supplements. Arch Intern Med. 2001;161:805–810
  30. Ashar BH, Miller RG, Pichard CP, et al. Patients’ understanding of the regulation of dietary supplements. J Community Health. 2008;32:22–30
  31. Ashar BH, Rice TN, Sisson SD. Physicians’ understanding of the regulation of dietary supplements. Arch Intern Med. 2007;167:966–969
  32. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. New York, NY: Oxford University Press; 1994;
  33. U.S. Food and Drug Administration. Dietary supplement current good manufacturing practices (CGMPs) and interim final rule (IFR) facts 2007. http://www.cfsan.fda.gov/∼dms/dscgmps6.htmlAccessed July 8, 2007
  34. Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John’s wort. Lancet. 2000;355:547–548
  35. Yue QY, Bergquist C, Gerden B. Safety of St John’s wort (Hypericum perforatum). Lancet. 2000;355:576–577
  36. Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther. 2001;70:518–524
  37. Bent S, Padula A, Neuhaus J. Safety and efficacy of citrus aurantium for weight loss. Am J Cardiol. 2004;94:1359–1361
  38. Nykamp DL, Fackih MN, Compton AL. Possible association of acute lateral-wall myocardial infarction and bitter orange supplement. Ann Pharmacother. 2004;38:812–816
  39. Bouchard NC, Howland MA, Greller HA, et al. Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clin Proc. 2005;80:541–545
  40. Nasir JM, Durning SJ, Ferguson M, et al. Exercise-induced syncope associated with QT prolongation and ephedra-free Xenadrine. Mayo Clin Proc. 2004;79:1059–1062
  41. Low Dog T. Menopause: a review of botanical dietary supplements. Am J Med. 2005;118(Suppl 12B):98–108
  42. Newton KM, Reed SD, LaCroix AZ, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med. 2006;145:869–879
  43. Lynch CR, Folkers ME, Hutson WR. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transpl. 2006;12:989–992
  44. Shekelle P, Morton SC, Hardy M. Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease. Evid Rep Technol Assess (Summ). 2003;(83):1–3
  45. Weber CA, Ernst ME. Antioxidants, supplements, and Parkinson’s disease. Ann Pharmacother. 2006;40:935–938
  46. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm. 2000;57:1221–1227
  47. Jepson RG, Mihaljevic L, Craig J. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2004;(2):CD001321
  48. Jepson RG, Mihaljevic L, Craig J. Cranberries for treating urinary tract infections. Cochrane Database Syst Rev. 1998;(2):CD001322
  49. Grant P. Warfarin and cranberry juice: an interaction?. J Heart Valve Dis. 2004;13:25–26
  50. Linde K, Barrett B, Wölkart K, et al. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2006;(1):CD000530
  51. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med. 1998;158:2200–2211
  52. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2002;(4):CD003120
  53. Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. J Gen Intern Med. 2005;20:657–661
  54. Gregory PJ. Seizure associated with Ginkgo biloba?. Ann Intern Med. 2001;134:344
  55. Vogler BK, Pittler MH, Ernst E. The efficacy of ginseng: a systematic review of randomized clinical trials. Eur J Clin Pharmacol. 1999;55:567
  56. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care. 2003;26:1277–1294
  57. Yuan CS Wei G, Dey L, et al. American ginseng reduces warfarin’s effect in healthy patients: a randomized controlled trial. Ann Intern Med. 2004;141:23
  58. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;(2):CD002946
  59. Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. Cochrane Database Syst Rev. 2003;(1):CD003383
  60. Clouatre DL. Kava kava: examining new reports of toxicity. Toxicol Lett. 2004;150:85–96
  61. Linde K, Mulrow CD, Berner M, Egger M. St John’s wort for depression. Cochrane Database Syst Rev. 2005;(3):CD000448
  62. U.S. Food and Drug Administration MedWatch System. http://www.fda.gov/medwatch/index.htmlAccessed October 2, 2007
  63. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis (A 3-year, randomized, placebo-controlled, double-blind study). Arch Intern Med. 2002;162:2113–2123
  64. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357:251–256

PII: S0002-9343(07)01136-9

doi: 10.1016/j.amjmed.2007.10.031

The American Journal of Medicine
Volume 121, Issue 2 , Pages 91-97 , February 2008

Article Tools